UPDATE ON A PHASE 1 STUDY OF THE SELECTIVE PI3K-DELTA INHIBITOR, IDELALISIB (GS-1101) IN COMBINATION WITH OFATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
HAEMATOLOGICA(2013)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined